BAUSCH Health

News Releases

Register for email alerts.

All Categories

Archive

Date 12/21/10

Title

Valeant Pharmaceuticals to Hold Conference Call to Announce 2011 Financial Guidance

Download PDF

Date 12/20/10

Title

Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO

Download PDF

Date 12/13/10

Title

Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman

Download PDF

Date 12/01/10

Title

GSK and Valeant announce receipt of U.S. FDA Complete Response letter for ezogabine

Download PDF

Date 11/23/10

Title

Valeant Pharmaceuticals to Present At Piper Jeffray 22nd Annual Health Care Conference

Download PDF

Date 11/18/10

Title

Valeant Launches Senior Notes Offering

Download PDF

Date 11/18/10

Title

Valeant Announces Pricing of Senior Notes

Download PDF

Date 11/04/10

Title

Valeant Pharmaceuticals and S.A.C Capital Settle Lawsuit

Download PDF

Date 11/04/10

Title

Valeant Announces A $1.5 Billion Securities Repurchase Program

Download PDF

Date 11/04/10

Title

Valeant Pharmaceuticals to Gradient Analytics Settle Lawsuit

Download PDF

Date 11/04/10

Title

Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan

Download PDF

Date 11/01/10

Title

Valeant Pharmaceuticals and Kadmon Announce Strategic Agreement for Antiviral Therapeutics

Download PDF

Date 10/29/10

Title

Valeant Pharmaceuticals to Acquire #2 Suncare Brand in Australia

Download PDF

Date 10/25/10

Title

Valeant Pharmaceuticals to Announce 2010 Third Quarter results on November 4, 2010

Download PDF

Date 10/11/10

Title

Valeant Pharmaceuticals Announces that Alexza Pharmaceuticals Has Received A Complete Response Letter For AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA

Download PDF

Date 09/28/10

Title

Valeant and Biovail Complete Merger

Download PDF

Date 09/27/10

Title

Valeant and Biovail Announce Results of Special Meetings of Shareholders

Download PDF

Date 09/27/10

Title

Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016

Download PDF

Date 09/22/10

Title

Valeant and Biovail Announce Valeant's Intention to Declare a Special Dividend to Valeant Stockholders upon Obtaining Shareholder Approval, Financing and Satisfaction of Other Closing Conditions

Download PDF

Date 09/22/10

Title

Valeant Announces Pricing of Senior Notes

Download PDF

Date 09/09/10

Title

Valeant Plans Senior Notes Offering and Begins Arrangement of New Credit Facilities

Download PDF

Date 08/30/10

Title

GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine

Download PDF

Date 08/11/10

Title

Valeant and Biovail Set Date for Shareholders Meetings

Download PDF

Date 08/11/10

Title

Ezogabine, an Investigational Anti-Epileptic Drug, Receives Positive Vote from FDA Advisory Committee

Download PDF

Date 08/05/10

Title

Biovail Reports Second-Quarter 2010 Financial Results

Download PDF

Date 08/05/10

Title

Biovail Declares Quarterly Dividend

Download PDF

Date 08/02/10

Title

Valeant Pharmaceuticals Reports 2010 Second Quarter Financial Results

Download PDF

Date 07/23/10

Title

Biovail Announces Second-Quarter 2010 Earnings Release, Conference-Call Details

Download PDF

Date 07/22/10

Title

Valeant Pharmaceuticals to Announce 2010 Second Quarter Results on August 2, 2010

Download PDF

Date 06/23/10

Title

Valeant Pharmaceuticals Resumes Shipment of Oxsoralen-Ultra(R)

Download PDF

Date 06/22/10

Title

Biovail and MedGenesis Announce Grant from The Michael J. Fox Foundation for the Development of GDNF

Download PDF

Date 06/21/10

Title

Valeant and Biovail Agree to Merge

Download PDF

Date 06/21/10

Title

Valeant and Biovail Agree to Merge

Download PDF

Date 06/03/10

Title

Biovail Enters into License Agreement with Kyowa Hakko Kirin

Download PDF

Date 06/03/10

Title

Valeant Pharmaceuticals to Host Investor Day

Download PDF

Date 05/27/10

Title

Valeant Pharmaceuticals Completes Acquisition of Aton Pharma, Inc.

Download PDF

Date 05/10/10

Title

Valeant Pharmaceuticals Announces Regulatory Approval of Onsolis(TM) in Canada

Download PDF

Date 05/06/10

Title

Biovail Reports First-Quarter 2010 Financial Results

Download PDF

Date 05/06/10

Title

Biovail Announces Increase to Quarterly Dividend

Download PDF

Date 05/04/10

Title

Valeant Pharmaceuticals to Webcast 2010 Annual Meeting of Stockholders

Download PDF

Date 05/03/10

Title

Valeant Pharmaceuticals Reports 2010 First Quarter Financial Results

Download PDF

Date 04/28/10

Title

Valeant to Acquire Vital Science Corp. in Canada

Download PDF

Date 04/23/10

Title

Valeant Pharmaceuticals to Announce 2010 First Quarter Results on May 3, 2010

Download PDF

Date 04/22/10

Title

Biovail Announces First-Quarter 2010 Earnings Release, Conference-Call Details

Download PDF

Date 04/21/10

Title

Valeant to Acquire Pharmaceutical Company in Brazil

Download PDF

Date 04/07/10

Title

Valeant Pharmaceuticals Announces Pricing of Senior Notes

Download PDF

Date 04/06/10

Title

Valeant Plans Senior Notes Offering

Download PDF

Date 03/30/10

Title

Valeant Announces Increase to Securities Repurchase Program

Download PDF

Date 03/26/10

Title

Biovail Acquires AMPAKINE(R) Compounds for Treatment of Respiratory Depression

Download PDF

Date 03/19/10

Title

Valeant to Acquire Branded Generics/OTC Company in Brazil

Download PDF

Date 03/18/10

Title

Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date

Download PDF

Date 03/02/10

Title

Valeant Pharmaceuticals to Present at Cowen and Company 30th Annual Health Care Conference

Download PDF

Date 03/01/10

Title

Valeant Enters Collaboration With Spear Pharmaceuticals

Download PDF

Date 02/25/10

Title

Biovail Reports Fourth Quarter, Year-End 2009 Financial Results

Download PDF

Date 02/25/10

Title

Biovail Declares Quarterly Dividend

Download PDF

Date 02/22/10

Title

Valeant Pharmaceuticals Reports 2009 Fourth Quarter and Full Year Financial Results

Download PDF

Date 02/19/10

Title

Biovail Comments on Filing of Complaints

Download PDF

Date 02/12/10

Title

Biovail Announces Fourth-Quarter 2009 Earnings Release, Conference-Call Details

Download PDF

Date 02/10/10

Title

Biovail Enters into License and Collaboration Agreement with Alexza for AZ-004

Download PDF

Date 02/08/10

Title

Valeant Pharmaceuticals to Announce 2009 Fourth Quarter and Year Results on February 22, 2010

Download PDF

Date 01/22/10

Title

Biovail Comments on Proposed Generic Wellbutrin XL(R) Trial

Download PDF

Date 01/06/10

Title

Biovail to Present at JPMorgan Healthcare Conference

Download PDF

Date 01/06/10

Title

Valeant Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

Download PDF

Date 01/05/10

Title

Valeant Pharmaceuticals to Hold Conference Call to Announce 2010 Financial Guidance

Download PDF

Investor Inquiries
ir@bauschhealth.com
877-281-6642
514-856-3855 (Canada)

Media inquiries
Corporate.communications@bauschhealth.com
848-264-0934

LEGAL NOTICE PRIVACY POLICY

EMAIL ALERTS EMAIL PAGE RSS FEED

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

Powered by SITECORE